Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06915233 · ClinicalTrials.gov registry record · Phase 3
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
A Phase 3 study of Chondral Defect and Articular Cartilage Defect, sponsored by Vericel Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 309
- Enrollment target
- 4
- Study locations
NCT06915233 is a Phase 3 study of Chondral Defect and Articular Cartilage Defect that is actively recruiting participants, run by Vericel Corporation. The registered enrollment target is 309 participants, above the 202-participant average among 3 other Chondral Defect trials with a reported enrollment target (53% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT06915233, a Phase 3 study of Chondral Defect and Articular Cartilage Defect, is actively recruiting participants, sponsored by Vericel Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 309 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus.
Conditions Studied
Interventions
- BIOLOGICAL autologous cultured chondrocytes on porcine collagen membrane
- PROCEDURE Bone Marrow Stimulation
Study Locations (4)
Texas
- NextStage Clinical Research Houston - All American Orthopedic and Sports Medicine - Houston
- NextStage Clinical Research San Antonio - San Antonino Podiatry Associates - San Antonio
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Kansas
- NextStage Clinical Research Wichita - Kansas Joint and Spine specialists - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2026-03 |
| Est. Completion | 2030-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06915233
The ClinicalTrials.gov registry entry for NCT06915233 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 3 other Chondral Defect trials with a reported enrollment target (53% higher). The listed sponsor is Vericel Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chondral Defect appearing as the primary indexed condition, and to 2 interventions - of which autologous cultured chondrocytes on porcine collagen membrane is the first listed.
NCT06915233 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, District of Columbia, Kansas.
Frequently Asked Questions
What is clinical trial NCT06915233 about?
NCT06915233 is a clinical study titled "A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle". The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus.
What is the current status of trial NCT06915233?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 309 participants. The study started on 2026-03. Estimated completion is 2030-07.
What conditions does trial NCT06915233 study?
This clinical trial studies the following conditions: Chondral Defect, Articular Cartilage Defect.
What interventions are being tested in trial NCT06915233?
The interventions under investigation include: autologous cultured chondrocytes on porcine collagen membrane (BIOLOGICAL), Bone Marrow Stimulation (PROCEDURE).
Who is sponsoring clinical trial NCT06915233?
This trial is sponsored by Vericel Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06915233 being conducted?
This trial has 4 study locations across District of Columbia, Kansas, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chondral Defect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies
RECRUITING · Phase 3
-
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
RECRUITING · Phase 3
-
Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear
RECRUITING
Explore more on PlainTrial
Chondral Defect
All registered trials for this condition
Articular Cartilage Defect
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.